Author

Baojia Yao

Observed name: Bao-Jia YAO

Institutions: Central South University, Second Xiangya Hospital of Central South University, Xiangya Hospital Central South University

Observed institutions: Central South University, Second Xiangya Hospital of Central South University, Xiangya Hospital Central South University

OpenAlex ID: A5113399352

Comprehensive assessment of cellular senescence in intestinal immunity and biologic therapy response in ulcerative colitis

2024 · Baojia Yao, Yawei Zhang, et al. · Scientific Reports · 14

Quantitative analysis of adipose tissue for predicting Crohn's disease postoperative endoscopic recurrence and anastomotic ulcer

2023 · Lichao Yang, Ganglei Liu, et al. · International Journal of Colorectal Disease · 13

A context-dependent METTL1-m7G-SLC7A11 axis links metabolic stress to epithelial fate in ulcerative colitis

2026 · Lichao Yang, Qi Sun, et al. · International Journal of Biological Sciences · 5

Timing of first abdominal operation in Crohn’s disease based on a diagnostic model

2024 · Lichao Yang, Yawei Zhang, et al. · Scientific Reports · 5

Epidemiological investigation of different types of Crohn’s disease patients undergoing first abdominal surgery in the era of biological agents: a population-based cohort study

2024 · Lichao Yang, Baojia Yao, et al. · International Journal of Colorectal Disease · 4

Mesenteric adipocytes promote intestinal fibrosis and inflammation in Crohn’s disease through epiregulin (EREG)

2025 · Yawei Zhang, Hengchang Yao, et al. · Translational research · 2

Integrating inflammatory and coagulation biomarkers for surgical risk stratification and treatment benefit assessment in Crohn’s disease

2026 · Kailing Xie, Qi Sun, et al. · Frontiers in Immunology · 1

Targeted delivery of nebivolol via lactoferrin-modified liposomes inhibits NEK7-mediated pyroptosis to ameliorate inflammatory bowel disease

2026 · Hengchang Yao, Lichao Yang, et al. · Free Radical Biology and Medicine

[Interpretable machine learning-based predictive model for assessing abdominal surgery risk and biologic therapy efficacy in CDAI 0 to 1 level Crohn disease patients].

2025 · Kailing Xie, Qi Sun, et al. · PubMed

Works count: 10

Citation count: 44

H-index: 4

I10-index: 2